Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de Gramont, A.
Right arrow Articles by Bedenne, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Gramont, A.
Right arrow Articles by Bedenne, L.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Journal of Clinical Oncology, Vol 15, 808-815, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study

A de Gramont, JF Bosset, C Milan, P Rougier, O Bouche, PL Etienne, F Morvan, C Louvet, T Guillot, E Francois and L Bedenne
Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD), Hopital Saint-Antoine, Paris, France.

PURPOSE: This multicenter study compared the therapeutic ratio of a monthly schedule of low-dose leucovorin (LV) and fluorouracil (5-FU) bolus with a bimonthly schedule of high-dose LV and 5-FU bolus plus continuous infusion in patients with advanced colorectal cancer. PATIENTS AND METHODS: Of the 448 patients randomly assigned to treatment, 433 were assessable. Treatment A was a monthly regimen of intravenous (IV) LV 20 mg/m2 plus bolus 5-FU 425 mg/m2 for 5 days every 4 weeks. Treatment B was a bimonthly regimen of IV LV 200 mg/m2 as a 2- hour infusion followed by bolus 5-FU 400 mg/m2 and 22-hour infusion 5- FU 600 mg/m2 for 2 consecutive days every 2 weeks. Therapy was continued until disease progression. Second-line chemotherapy, which included 5-FU continuous infusion, was allowed in both arms. RESULTS: The response rates in 348 patients with measurable lesions were 14.4% (monthly regimen) and 32.6% (bimonthly regimen) (P = .0004). The median progression-free survival times were 22 weeks (monthly regimen) and 27.6 weeks (bimonthly regimen) (P = .0012). The median survival times were 56.8 weeks (monthly regimen) and 62 weeks (bimonthly regimen) (P = .067). Grade 3-4 toxicities occurred in 23.9% of patients in the monthly arm compared with 11.1% of those in the bimonthly arm (P = .0004). Patients in arm A more frequently experienced severe granulocytopenia (7.3% v 1.9%), diarrhea (7.3% v 2.9%), and mucositis (7.3% v 1.9%) than patients in arm B. CONCLUSION: The bimonthly regimen was more effective and less toxic than the monthly regimen and definitely increased the therapeutic ratio. However, there was no evidence of increased survival.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
T. Andre, C. Boni, M. Navarro, J. Tabernero, T. Hickish, C. Topham, A. Bonetti, P. Clingan, J. Bridgewater, F. Rivera, et al.
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial
J. Clin. Oncol., July 1, 2009; 27(19): 3109 - 3116.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Ychou, W. Hohenberger, S. Thezenas, M. Navarro, J. Maurel, C. Bokemeyer, E. Shacham-Shmueli, F. Rivera, C. Kwok-Keung Choi, and A. Santoro
A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer
Ann. Onc., June 30, 2009; (2009) mdp236v1.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C.-H. Kohne and H.-J. Lenz
Chemotherapy with Targeted Agents for the Treatment of Metastatic Colorectal Cancer
Oncologist, May 1, 2009; 14(5): 478 - 488.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. Aranda, M. Valladares, M. Martinez-Villacampa, M. Benavides, A. Gomez, B. Massutti, E. Marcuello, M. Constenla, J. C. Camara, A. Carrato, et al.
Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study
Ann. Onc., February 1, 2009; 20(2): 251 - 257.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Schlemmer, M. Kuehl, A. Schalhorn, J. Rauch, K.-W. Jauch, and M. Hentrich
Tissue Levels of Reduced Folates in Patients with Colorectal Carcinoma After Infusion of Folinic Acid at Various Dose Levels
Clin. Cancer Res., December 1, 2008; 14(23): 7930 - 7934.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Gamelin, R. Delva, J. Jacob, Y. Merrouche, J. L. Raoul, D. Pezet, E. Dorval, G. Piot, A. Morel, and M. Boisdron-Celle
Individual Fluorouracil Dose Adjustment Based on Pharmacokinetic Follow-Up Compared With Conventional Dosage: Results of a Multicenter Randomized Trial of Patients With Metastatic Colorectal Cancer
J. Clin. Oncol., May 1, 2008; 26(13): 2099 - 2105.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. G. Haller, J. Cassidy, S. J. Clarke, D. Cunningham, E. Van Cutsem, P. M. Hoff, M. L. Rothenberg, L. B. Saltz, H.-J. Schmoll, C. Allegra, et al.
Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines
J. Clin. Oncol., May 1, 2008; 26(13): 2118 - 2123.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B. Glimelius, H. Sorbye, L. Balteskard, P. Bystrom, P. Pfeiffer, K. Tveit, R. Heikkila, N. Keldsen, M. Albertsson, H. Starkhammar, et al.
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer
Ann. Onc., May 1, 2008; 19(5): 909 - 914.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. J. Twelves
Defining the Optimal Schedule of Drug Administration: Art or Science?
J. Clin. Oncol., April 10, 2008; 26(11): 1781 - 1782.
[Full Text] [PDF]

Home page
 Ann OncolHome page
A. Pessino, S. Artale, S. Sciallero, A. Guglielmi, G. Fornarini, I.C. Andreotti, S. Mammoliti, D. Comandini, F. Caprioni, E. Bennicelli, et al.
First-line single-agent cetuximab in patients with advanced colorectal cancer
Ann. Onc., April 1, 2008; 19(4): 711 - 716.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. R. Zalcberg, L. S. Rosen, E. Abdi, I. D. Davis, J. Gutheil, F. M. Schnell, A. Cesano, U. Gayko, M.-G. Chen, and S. Clarke
Role of Palifermin in Fluorouracil-Based Therapy for Metastatic Colorectal Cancer
J. Clin. Oncol., March 10, 2008; 26(8): 1386 - 1387.
[Full Text] [PDF]

Home page
 The OncologistHome page
T. M. Pawlik, R. D. Schulick, and M. A. Choti
Expanding Criteria for Resectability of Colorectal Liver Metastases
Oncologist, January 1, 2008; 13(1): 51 - 64.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. S. Hochster, W. Luo, E. C. Popa, B. T. Lyman, M. Mulcahy, P. A. Beatty, and A. B. Benson
Phase II Study of Uracil-Tegafur With Leucovorin in Elderly (>= 75 years old) Patients With Colorectal Cancer: ECOG 1299
J. Clin. Oncol., December 1, 2007; 25(34): 5397 - 5402.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
Y. Becouarn, P. Senesse, S. Thezenas, E. Boucher, A. Adenis, L. Cany, J. H. Jacob, F. Cvitkovic, C. Montoto-Grillot, and M. Ychou
A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Federation Nationale des Centres de Lutte Contre le Cancer
Ann. Onc., December 1, 2007; 18(12): 2000 - 2005.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. A. Tang, S. M. Bentzen, E. X. Chen, and L. L. Siu
Surrogate End Points for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis From 39 Randomized Controlled Trials of First-Line Chemotherapy
J. Clin. Oncol., October 10, 2007; 25(29): 4562 - 4568.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
S.-G. Kim, S. Y. Oh, H.-C. Kwon, S. Lee, J. H. Kim, S.-H. Kim, and H.-J. Kim
A Phase II Study of Irinotecan with Bi-weekly, Low-dose Leucovorin and Bolus and Continuous Infusion 5-fluorouracil (Modified FOLFIRI) as Salvage Therapy for Patients with Advanced or Metastatic Gastric Cancer
Jpn. J. Clin. Oncol., October 8, 2007; (2007) hym103v1.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
O. Tredan, C. M. Galmarini, K. Patel, and I. F. Tannock
Drug Resistance and the Solid Tumor Microenvironment
J Natl Cancer Inst, October 3, 2007; 99(19): 1441 - 1454.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
G. A. Hospers, C. J. A. Punt, M. E. Tesselaar, A. Cats, K. Havenga, J. W. H. Leer, C. A. Marijnen, E. P. Jansen, H. H. J. M. Van Krieken, T. Wiggers, et al.
Preoperative Chemoradiotherapy with Capecitabine and Oxaliplatin in Locally Advanced Rectal Cancer. A Phase I II Multicenter Study of the Dutch Colorectal Cancer Group
Ann. Surg. Oncol., October 1, 2007; 14(10): 2773 - 2779.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Andre, E. Quinaux, C. Louvet, P. Colin, E. Gamelin, O. Bouche, E. Achille, P. Piedbois, N. Tubiana-Mathieu, A. Boutan-Laroze, et al.
Phase III Study Comparing a Semimonthly With a Monthly Regimen of Fluorouracil and Leucovorin As Adjuvant Treatment for Stage II and III Colon Cancer Patients: Final Results of GERCOR C96.1
J. Clin. Oncol., August 20, 2007; 25(24): 3732 - 3738.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. S. Siegel-Lakhai, J. H. Beijnen, W. L. Vervenne, H. Boot, M. Keessen, M. Versola, K. M. Koch, D. A. Smith, L. Pandite, D. J. Richel, et al.
Phase I Pharmacokinetic Study of the Safety and Tolerability of Lapatinib (GW572016) in Combination with Oxaliplatin/Fluorouracil/Leucovorin (FOLFOX4) in Patients with Solid Tumors
Clin. Cancer Res., August 1, 2007; 13(15): 4495 - 4502.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
I. E. Haines
Questions About the Role of Palifermin in Fluorouracil-Based Therapy for Metastatic Colorectal Cancer
J. Clin. Oncol., July 1, 2007; 25(19): e24 - e25.
[Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
B. M. Wolpin, J. A. Meyerhardt, H. J. Mamon, and R. J. Mayer
Adjuvant Treatment of Colorectal Cancer
CA Cancer J Clin, May 1, 2007; 57(3): 168 - 185.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Murata and M. Moriyama
Isoleucine, an Essential Amino Acid, Prevents Liver Metastases of Colon Cancer by Antiangiogenesis
Cancer Res., April 1, 2007; 67(7): 3263 - 3268.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A.-R. Hanauske, J. Cassidy, J. Sastre, C. Bolling, R. J. Jones, A. Rakhit, S. Fettner, U. Brennscheidt, A. Feyereislova, and E. Diaz-Rubio
Phase 1b Dose Escalation Study of Erlotinib in Combination with Infusional 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Advanced Solid Tumors
Clin. Cancer Res., January 15, 2007; 13(2): 523 - 531.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. M. Goldberg, M. L. Rothenberg, E. Van Cutsem, A. B. Benson III, C. D. Blanke, R. B. Diasio, A. Grothey, H.-J. Lenz, N. J. Meropol, R. K. Ramanathan, et al.
The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer
Oncologist, January 1, 2007; 12(1): 38 - 50.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Morel, M. Boisdron-Celle, L. Fey, P. Soulie, M. C. Craipeau, S. Traore, and E. Gamelin
Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance.
Mol. Cancer Ther., November 1, 2006; 5(11): 2895 - 2904.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M Gusella, G Crepaldi, C Barile, A Bononi, D Menon, S Toso, D Scapoli, L Stievano, E Ferrazzi, F Grigoletto, et al.
Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer
Ann. Onc., November 1, 2006; 17(11): 1656 - 1660.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. M. Goldberg
Therapy for Metastatic Colorectal Cancer
Oncologist, October 1, 2006; 11(9): 981 - 987.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. M. Goldberg, D. J. Sargent, R. F. Morton, C. S. Fuchs, R. K. Ramanathan, S. K. Williamson, B. P. Findlay, H. C. Pitot, and S. Alberts
Randomized Controlled Trial of Reduced-Dose Bolus Fluorouracil Plus Leucovorin and Irinotecan or Infused Fluorouracil Plus Leucovorin and Oxaliplatin in Patients With Previously Untreated Metastatic Colorectal Cancer: A North American Intergroup Trial
J. Clin. Oncol., July 20, 2006; 24(21): 3347 - 3353.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
I. Hyodo, K. Shirao, T. Doi, K. Hatake, Y. Arai, K. Yamaguchi, T. Tamura, S. Takemiya, H. Takiuchi, K. Nakagawa, et al.
A Phase II Study of the Global Dose and Schedule of Capecitabine in Japanese Patients with Metastatic Colorectal Cancer
Jpn. J. Clin. Oncol., July 1, 2006; 36(7): 410 - 417.
[Abstract] [Full Text] [PDF]

Home page
 DTBHome page
{blacktriangledown}Bevacizumab and {blacktriangledown}cetuximab for colorectal cancer
DTB, May 1, 2006; 44(5): 37 - 40.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
Y. Yamada, A. Ohtsu, N. Boku, Y. Miyata, Y. Shimada, T. Doi, K. Muro, M. Muto, T. Hamaguchi, K. Mera, et al.
Phase I/II Study of Oxaliplatin with Weekly Bolus Fluorouracil and High-Dose Leucovorin (ROX) As First-Line Therapy for Patients with Colorectal Cancer.
Jpn. J. Clin. Oncol., April 1, 2006; 36(4): 218 - 223.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. A. P. Hospers, M. Schaapveld, J. W. R. Nortier, J. Wils, A. van Bochove, R. S. de Jong, G. J. Creemers, Z. Erjavec, D. J. de Gooyer, P. H. Th. J. Slee, et al.
Randomised Phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer
Ann. Onc., March 1, 2006; 17(3): 443 - 449.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C.-H. Kohne and G. Folprecht
On prejudice and facts and choices
Ann. Onc., February 1, 2006; 17(2): 185 - 187.
[Full Text] [PDF]

Home page
 Ann OncolHome page
C. Twelves, S. Gollins, R. Grieve, and L. Samuel
A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer
Ann. Onc., February 1, 2006; 17(2): 239 - 245.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Tournigand, A. Cervantes, A. Figer, G. Lledo, M. Flesch, M. Buyse, L. Mineur, E. Carola, P.-L. Etienne, F. Rivera, et al.
OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer--A GERCOR Study
J. Clin. Oncol., January 20, 2006; 24(3): 394 - 400.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. Hata, H. Yamamoto, C. Y. Ngan, M. Koi, A. Takagi, B. Damdinsuren, M. Yasui, Y. Fujie, T. Matsuzaki, H. Hemmi, et al.
Role of p21waf1/cip1 in effects of oxaliplatin in colorectal cancer cells
Mol. Cancer Ther., October 1, 2005; 4(10): 1585 - 1594.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
J. Sakamoto, C. Hamada, M. Rahman, S. Kodaira, K. Ito, H. Nakazato, Y. Ohashi, and M. Yasutomi
An Individual Patient Data Meta-analysis of Adjuvant Therapy with Carmofur in Patients with Curatively Resected Colon Cancer
Jpn. J. Clin. Oncol., September 1, 2005; 35(9): 536 - 544.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
Y. Fujie, H. Yamamoto, C. Y. Ngan, A. Takagi, T. Hayashi, R. Suzuki, K. Ezumi, I. Takemasa, M. Ikeda, M. Sekimoto, et al.
Oxaliplatin, a Potent Inhibitor of Survivin, Enhances Paclitaxel-induced Apoptosis and Mitotic Catastrophe in Colon Cancer Cells
Jpn. J. Clin. Oncol., August 1, 2005; 35(8): 453 - 463.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Colucci, V. Gebbia, G. Paoletti, F. Giuliani, M. Caruso, N. Gebbia, G. Carteni, B. Agostara, G. Pezzella, L. Manzione, et al.
Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell'Italia Meridionale
J. Clin. Oncol., August 1, 2005; 23(22): 4866 - 4875.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C.-H. Kohne, E. van Cutsem, J. Wils, C. Bokemeyer, M. El-Serafi, M.P. Lutz, M. Lorenz, P. Reichardt, H. Ruckle-Lanz, N. Frickhofen, et al.
Phase III Study of Weekly High-Dose Infusional Fluorouracil Plus Folinic Acid With or Without Irinotecan in Patients With Metastatic Colorectal Cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986
J. Clin. Oncol., August 1, 2005; 23(22): 4856 - 4865.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Ducreux, M. Ychou, A. Laplanche, E. Gamelin, P. Lasser, F. Husseini, F. Quenet, F. Viret, J.-H. Jacob, V. Boige, et al.
Hepatic Arterial Oxaliplatin Infusion Plus Intravenous Chemotherapy in Colorectal Cancer With Inoperable Hepatic Metastases: A Trial of the Gastrointestinal Group of the Federation Nationale des Centres de Lutte Contre le Cancer
J. Clin. Oncol., August 1, 2005; 23(22): 4881 - 4887.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. Kelly and R. M. Goldberg
Systemic Therapy for Metastatic Colorectal Cancer: Current Options, Current Evidence
J. Clin. Oncol., July 10, 2005; 23(20): 4553 - 4560.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. Comella, B. Massidda, G. Filippelli, S. Palmeri, D. Natale, A. Farris, F. De Vita, F. Buzzi, S. Tafuto, L. Maiorino, et al.
Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial
Ann. Onc., June 1, 2005; 16(6): 878 - 886.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. A. Wright, G. Morrison, P. Lin, G. D. Leonard, D. Nguyen, X. Guo, E. Szabo, J. L. Hopkins, J. P. Leguizamo, N. Harold, et al.
A Phase I Pharmacologic and Pharmacogenetic Trial of Sequential 24-Hour Infusion of Irinotecan Followed by Leucovorin and a 48-Hour Infusion of Fluorouracil in Adult Patients with Solid Tumors
Clin. Cancer Res., June 1, 2005; 11(11): 4144 - 4150.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
N. Meydan, I. Kundak, T. Yavuzsen, I. Oztop, S. Barutca, U. Yilmaz, and M. N. Alakavuklar
Cardiotoxicity of de Gramont's Regimen: Incidence, Clinical Characteristics and Long-term Follow-up
Jpn. J. Clin. Oncol., May 1, 2005; 35(5): 265 - 270.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Venook
Critical Evaluation of Current Treatments in Metastatic Colorectal Cancer
Oncologist, April 1, 2005; 10(4): 250 - 261.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
H. S Sano, J A. Waddell, D. A Solimando Jr, P. Doulaveris, and R. Myhand
Study of the effect of standardized chemotherapy order forms on prescribing errors and anti-emetic cost
Journal of Oncology Pharmacy Practice, March 1, 2005; 11(1): 21 - 30.
[Abstract] [PDF]

Home page
 NEJMHome page
J. A. Meyerhardt and R. J. Mayer
Systemic Therapy for Colorectal Cancer
N. Engl. J. Med., February 3, 2005; 352(5): 476 - 487.
[Full Text] [PDF]

Home page
 JCOHome page
N. Kemeny, C. A. Garay, J. Gurtler, H. Hochster, P. Kennedy, A. Benson, D. Schwab Brandt, J. Polikoff, M. Wertheim, G. Shumaker, et al.
Randomized Multicenter Phase II Trial of Bolus Plus Infusional Fluorouracil/Leucovorin Compared With Fluorouracil/Leucovorin Plus Oxaliplatin As Third-Line Treatment of Patients With Advanced Colorectal Cancer
J. Clin. Oncol., December 1, 2004; 22(23): 4753 - 4761.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
O. Bouche, J. L. Raoul, F. Bonnetain, M. Giovannini, P. L. Etienne, G. Lledo, D. Arsene, J. F. Paitel, V. Guerin-Meyer, E. Mitry, et al.
Randomized Multicenter Phase II Trial of a Biweekly Regimen of Fluorouracil and Leucovorin (LV5FU2), LV5FU2 Plus Cisplatin, or LV5FU2 Plus Irinotecan in Patients With Previously Untreated Metastatic Gastric Cancer: A Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803
J. Clin. Oncol., November 1, 2004; 22(21): 4319 - 4328.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Folprecht, D. Cunningham, P. Ross, B. Glimelius, F. Di Costanzo, J. Wils, W. Scheithauer, P. Rougier, E. Aranda, H. Hecker, et al.
Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials
Ann. Onc., September 1, 2004; 15(9): 1330 - 1338.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Lal, J. Dickson, D. Cunningham, I. Chau, A. R. Norman, P. J. Ross, C. Topham, G. Middleton, M. Hill, and J. Oates
A Randomized Trial Comparing Defined-Duration With Continuous Irinotecan Until Disease Progression in Fluoropyrimidine and Thymidylate Synthase Inhibitor--Resistant Advanced Colorectal Cancer
J. Clin. Oncol., August 1, 2004; 22(15): 3023 - 3031.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Q. S.-C. Chu, L. A. Hammond, G. Schwartz, L. Ochoa, S.-Y. Rha, L. Denis, K. Molpus, B. Roedig, S. P. Letrent, B. Damle, et al.
Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine S-1 on a Once-Daily-for-28-Day Schedule in Patients with Advanced Malignancies
Clin. Cancer Res., August 1, 2004; 10(15): 4913 - 4921.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
J. J. Lee, T. M. Kim, S. J. Yu, D.-W. Kim, Y.-h. Joh, D.-Y. Oh, J. H. Kwon, T. Y. Kim, D. S. Heo, Y.-J. Bang, et al.
Single-agent Capecitabine in Patients with Metastatic Colorectal Cancer Refractory to 5-Fluorouracil/Leucovorin Chemotherapy
Jpn. J. Clin. Oncol., July 1, 2004; 34(7): 400 - 404.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. Mitry, J.-Y. Douillard, E. Van Cutsem, D. Cunningham, E. Magherini, D. Mery-Mignard, L. Awad, and P. Rougier
Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials
Ann. Onc., July 1, 2004; 15(7): 1013 - 1017.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L. Cals, O. Rixe, E. Francois, R. Favre, L. Merad, G. Deplanque, A. Laadem, P. Juin, J. M. Bereder, D. Bernardini, et al.
Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients
Ann. Onc., July 1, 2004; 15(7): 1018 - 1024.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
T. Andre, C. Boni, L. Mounedji-Boudiaf, M. Navarro, J. Tabernero, T. Hickish, C. Topham, M. Zaninelli, P. Clingan, J. Bridgewater, et al.
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
N. Engl. J. Med., June 3, 2004; 350(23): 2343 - 2351.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Cassidy, J. Tabernero, C. Twelves, R. Brunet, C. Butts, T. Conroy, F. Debraud, A. Figer, J. Grossmann, N. Sawada, et al.
XELOX (Capecitabine Plus Oxaliplatin): Active First-Line Therapy for Patients With Metastatic Colorectal Cancer
J. Clin. Oncol., June 1, 2004; 22(11): 2084 - 2091.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
E. Diaz-Rubio
New Chemotherapeutic Advances in Pancreatic, Colorectal, and Gastric Cancers
Oncologist, June 1, 2004; 9(3): 282 - 294.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
Y. Kondo, M. Terashima, A. Sato, and T. Taguchi
A Pilot Phase II Study of Capecitabine in Advanced or Recurrent Colorectal Cancer
Jpn. J. Clin. Oncol., April 1, 2004; 34(4): 195 - 201.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
Efficacy of Oral Adjuvant Therapy After Resection of Colorectal Cancer: 5-Year Results From Three Randomized Trials
J. Clin. Oncol., February 1, 2004; 22(3): 484 - 492.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Tournigand, T. Andre, E. Achille, G. Lledo, M. Flesh, D. Mery-Mignard, E. Quinaux, C. Couteau, M. Buyse, G. Ganem, et al.
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study
J. Clin. Oncol., January 15, 2004; 22(2): 229 - 237.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. M. Goldberg, D. J. Sargent, R. F. Morton, C. S. Fuchs, R. K. Ramanathan, S. K. Williamson, B. P. Findlay, H. C. Pitot, and S. R. Alberts
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer
J. Clin. Oncol., January 1, 2004; 22(1): 23 - 30.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. D. Cohen and N. E. Kemeny
An Update on Hepatic Arterial Infusion Chemotherapy for Colorectal Cancer
Oncologist, December 1, 2003; 8(6): 553 - 566.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. P. Goetz, C. Erlichman, A. J. Windebank, J. M. Reid, J. A. Sloan, P. Atherton, A. A. Adjei, J. Rubin, H. Pitot, E. Galanis, et al.
Phase I and Pharmacokinetic Study of Two Different Schedules of Oxaliplatin, Irinotecan, Fluorouracil, and Leucovorin in Patients With Solid Tumors
J. Clin. Oncol., October 15, 2003; 21(20): 3761 - 3769.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. B. Saltz
Another Study of How to Give Fluorouracil?
J. Clin. Oncol., October 15, 2003; 21(20): 3711 - 3712.
[Full Text] [PDF]

Home page
 JCOHome page
C-H. Kohne, J. Wils, M. Lorenz, P. Schoffski, R. Voigtmann, C. Bokemeyer, M. Lutz, U. Kleeberg, K. Ridwelski, R. Souchon, et al.
Randomized Phase III Study of High-Dose Fluorouracil Given As a Weekly 24-Hour Infusion With or Without Leucovorin Versus Bolus Fluorouracil Plus Leucovorin in Advanced Colorectal Cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952
J. Clin. Oncol., October 15, 2003; 21(20): 3721 - 3728.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Fallik, F. Borrini, V. Boige, J. Viguier, S. Jacob, C. Miquel, J.-C. Sabourin, M. Ducreux, and F. Praz
Microsatellite Instability Is a Predictive Factor of the Tumor Response to Irinotecan in Patients with Advanced Colorectal Cancer
Cancer Res., September 15, 2003; 63(18): 5738 - 5744.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H. J. Mackay, M. Hill, C. Twelves, R. Glasspool, T. Price, S. Campbell, A. Massey, M. A. Macham, M. Uzzel, S. M. Bailey, et al.
A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer
Ann. Onc., August 1, 2003; 14(8): 1264 - 1269.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Andre, P. Colin, C. Louvet, E. Gamelin, O. Bouche, E. Achille, N. Colbert, C. Boaziz, P. Piedbois, N. Tubiana-Mathieu, et al.
Semimonthly Versus Monthly Regimen of Fluorouracil and Leucovorin Administered for 24 or 36 Weeks as Adjuvant Therapy in Stage II and III Colon Cancer: Results of a Randomized Trial
J. Clin. Oncol., August 1, 2003; 21(15): 2896 - 2903.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. Hochster, A. Chachoua, J. Speyer, J. Escalon, A. Zeleniuch-Jacquotte, and F. Muggia
Oxaliplatin With Weekly Bolus Fluorouracil and Low-Dose Leucovorin as First-Line Therapy for Patients With Colorectal Cancer
J. Clin. Oncol., July 15, 2003; 21(14): 2703 - 2707.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Fallik, M. Ychou, J. Jacob, P. Colin, J. F. Seitz, J. Baulieux, A. Adenis, J. Y. Douillard, P. Couzigou, R. Mahjoubi, et al.
Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: a phase II study in patients with nonresectable liver metastases from colorectal cancer
Ann. Onc., June 1, 2003; 14(6): 856 - 863.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Ychou, T. Conroy, J. F. Seitz, S. Gourgou, A. Hua, D. Mery-Mignard, and A. Kramar
An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors
Ann. Onc., March 1, 2003; 14(3): 481 - 489.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Masci, M. Magagnoli, P. A. Zucali, L. Castagna, C. Carnaghi, B. Sarina, V. Pedicini, M. Fallini, and A. Santoro
Minidose Warfarin Prophylaxis for Catheter-Associated Thrombosis in Cancer Patients: Can It Be Safely Associated With Fluorouracil-Based Chemotherapy?
J. Clin. Oncol., February 15, 2003; 21(4): 736 - 739.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B. Glimelius, R. Ristamaki, M. Kjaer, P. Pfeiffer, T. Skovsgaard, K. M. Tveit, T. Linne, J. E. Frodin, B. Boussard, D. Oulid-Aissa, et al.
Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer
Ann. Onc., December 1, 2002; 13(12): 1868 - 1873.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Aschele, D. Debernardis, R. Bandelloni, S. Cascinu, V. Catalano, P. Giordani, S. Barni, D. Turci, G. Drudi, S. Lonardi, et al.
Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil
Ann. Onc., December 1, 2002; 13(12): 1882 - 1892.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
V Trillet-Lenoir, G Freyer, P Kaemmerlen, A Fond, O Pellet, C Lombard-Bohas, J L Gaudin, G Lledo, R Mackiewicz, M C Gouttebel, et al.
Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria
Br. J. Radiol., November 1, 2002; 75(899): 903 - 908.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. Rougier, D. Lepille, J. Bennouna, A. Marre, M. Ducreux, L. Mignot, A. Hua, and D. Mery-Mignard
Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study
Ann. Onc., October 1, 2002; 13(10): 1558 - 1567.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. M. Goldberg, S. H. Kaufmann, P. Atherton, J. A. Sloan, A. A. Adjei, H. C. Pitot, S. R. Alberts, J. Rubin, L. L. Miller, and C. Erlichman
A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin
Ann. Onc., October 1, 2002; 13(10): 1674 - 1680.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
N. Kemeny, W. Tong, M. Gonen, J. Stockman, C. Di Lauro, J. Teitcher, P. White, C. Price, L. Saltz, S. Sharma, et al.
Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer
Ann. Onc., September 1, 2002; 13(9): 1490 - 1496.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Attoub, C. Rivat, S. Rodrigues, S. Van Bocxlaer, M. Bedin, E. Bruyneel, C. Louvet, M. Kornprobst, T. Andre, M. Mareel, et al.
The c-kit Tyrosine Kinase Inhibitor STI571 for Colorectal Cancer Therapy
Cancer Res., September 1, 2002; 62(17): 4879 - 4883.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J.-Y. Douillard, P. M. Hoff, J. R. Skillings, P. Eisenberg, N. Davidson, P. Harper, M. D. Vincent, B. C. Lembersky, S. Thompson, A. Maniero, et al.
Multicenter Phase III Study of Uracil/Tegafur and Oral Leucovorin Versus Fluorouracil and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer
J. Clin. Oncol., September 1, 2002; 20(17): 3605 - 3616.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Taieb, E. Mitry, V. Boige, P. Artru, J. Ezenfis, T. Lecomte, M. C. Clavero-Fabri, J. N. Vaillant, P. Rougier, and M. Ducreux
Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma
Ann. Onc., August 1, 2002; 13(8): 1192 - 1196.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
M. Rowe, J. W Valle, R. Swindell, L. Fitzsimmons, and R. D James
New face for a familiar friend: the deGramont regimen in the treatment of metastatic colorectal cancer given as an outpatient: a feasibility study
Journal of Oncology Pharmacy Practice, June 1, 2002; 8(2-3): 97 - 103.
[Abstract] [PDF]

Home page
 JCOHome page
A. Ravaioli, M. Marangolo, E. Pasquini, A. Rossi, D. Amadori, G. Cruciani, D. Tassinari, G. Oliverio, P. Giovanis, D. Turci, et al.
Bolus Fluorouracil and Leucovorin With Oxaliplatin as First-Line Treatment in Metastatic Colorectal Cancer
J. Clin. Oncol., May 15, 2002; 20(10): 2545 - 2550.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Cascinu, F. Graziano, F. Ferrau, V. Catalano, C. Massacesi, D. Santini, R. R. Silva, S. Barni, A. Zaniboni, N. Battelli, et al.
Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD)
Ann. Onc., May 1, 2002; 13(5): 716 - 720.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. Cure, V. Chevalier, A. Adenis, N. Tubiana-Mathieu, G. Niezgodzki, F. Kwiatkowski, D. Pezet, B. Perpoint, B. Coudert, C. Focan, et al.
Phase II Trial of Chronomodulated Infusion of High-Dose Fluorouracil and l-Folinic Acid in Previously Untreated Patients With Metastatic Colorectal Cancer
J. Clin. Oncol., March 1, 2002; 20(5): 1175 - 1181.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
M. Summerhayes
Capecitabine: a novel, orally administered, tumour-activated treatment for colorectal cancer
Journal of Oncology Pharmacy Practice, December 1, 2001; 7(4): 107 - 125.
[Abstract] [PDF]

Home page
 Jpn J Clin OncolHome page
T.-S. Yang, K.-C. Hsu, H.-M. Wang, and Y.-C. Lin
Phase II Study of a Weekly 8-Hour 5-Fluorouracil and Leucovorin Infusion for Patients with Advanced Colorectal Cancer: Dose Adjusted According to its Toxicity
Jpn. J. Clin. Oncol., December 1, 2001; 31(12): 610 - 615.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
Y. Becouarn, E. Gamelin, B. Coudert, S. Negrier, J.-Y. Pierga, J.-L. Raoul, J. Provencal, O. Rixe, C. Krisch, C. Germa, et al.
Randomized Multicenter Phase II Study Comparing a Combination of Fluorouracil and Folinic Acid and Alternating Irinotecan and Oxaliplatin With Oxaliplatin and Irinotecan in Fluorouracil-Pretreated Metastatic Colorectal Cancer Patients
J. Clin. Oncol., November 15, 2001; 19(22): 4195 - 4201.
[Abstract] [Full Text]

Home page
 JCOHome page
E. Van Cutsem, C. Twelves, J. Cassidy, D. Allman, E. Bajetta, M. Boyer, R. Bugat, M. Findlay, S. Frings, M. Jahn, et al.
Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III Study
J. Clin. Oncol., November 1, 2001; 19(21): 4097 - 4106.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
E. V. Cutsem, J.-Y. Douillard, and C.-H. Kohne
Toxicity of Irinotecan in Patients with Colorectal Cancer
N. Engl. J. Med., November 1, 2001; 345(18): 1351 - 1352.
[Full Text] [PDF]

Home page
 The OncologistHome page
M. Borner, W. Scheithauer, C. Twelves, J. Maroun, and H. Wilke
Answering Patients' Needs: Oral Alternatives to Intravenous Therapy
Oncologist, August 1, 2001; 6(2008): 12 - 16.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1997 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online